138 studies found for:
Peripheral Arterial Disease OR claudication OR peripheral vascular disease | Open Studies | NIH, U.S. Fed
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 21 | Recruiting |
Clinical Trial of a Silver Eluting Dressing System
|
||||
| 22 | Recruiting |
A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease
|
||||
| 23 | Recruiting |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer
|
||||
| 24 | Recruiting |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
|
||||
| 25 | Recruiting |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
||||
| 26 | Recruiting |
Donor Atorvastatin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplantation
|
||||
| 27 | Recruiting |
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
|
||||
| 28 | Recruiting |
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
|
||||
| 29 | Recruiting |
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
|
||||
| 30 | Recruiting |
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-Cell Lymphoma
|
||||
| 31 | Recruiting |
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
||||
| 32 | Recruiting |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
||||
| 33 | Recruiting |
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
|
||||
| 34 | Recruiting |
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
|
||||
| 35 | Recruiting |
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
|
||||
| 36 | Not yet recruiting |
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
|
||||
| 37 | Recruiting |
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
|
||||
| 38 | Not yet recruiting |
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
|
||||
| 39 | Recruiting |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
|
||||
| 40 | Recruiting |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
|
† Indicates status has not been verified in more than two years

